Evidence map›Paper›PMID 39953381›Full record

Observational studyThe journal of headache and pain2025

Physical activity as a predictor of fremanezumab response in chronic migraine - the Phy-Fre-Mig study.

Álvaro Sierra-Mencía, Andrea Recio-García, David García-Azorín, Antonio José Molina de la Torre, Isabel Ros González, Ángel Luis Guerrero-Peral

Abstract readObservational Study
In one paragraph

Observational study in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Álvaro Sierra-MencíaHeadache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. alvarosierramencia@gmail.com.ORCID http://orcid.org/0000-0002-0022-6064
Andrea Recio-GarcíaHeadache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
David García-AzorínNeurology Department, Hospital Universitario Río Hortega, Valladolid, Spain.ORCID http://orcid.org/0000-0002-3132-1064
Antonio José Molina de la TorreÁrea de medicina preventiva y salud pública, University of León, León, Spain.ORCID http://orcid.org/0000-0002-5948-6397
Isabel Ros GonzálezHeadache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Ángel Luis Guerrero-PeralHeadache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.ORCID http://orcid.org/0000-0001-7493-6002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between physical activity (PA) and migraine is insufficiently understood. Studies have not analysed levels of PA or Time Sitting (TS) during preventive treatment, nor the role these might play in the response to preventive treatment.

methodsAn observational, longitudinal prospective study in a headache clinic was conducted. All consecutive chronic migraine patients initiating fremanezumab were invited to participate and were followed for three visits. The International Physical Activity Questionnaire (IPAQ) - long version was used.

resultsSeventy-six patients with a median of 46 years old, 84.2% female were enrolled. One month after fremanezumab administration, there was a significant increase of most PA variables and a significant decrease in TS levels compared with baseline; headache days and walking, TS and migraine days showed a moderate correlation. Three months after initiation, all PA variables statistically increased and TS levels statistically decreased, and variables such as headache/migraine days showed a moderate correlation with all PA variables analysed. In the multivariate analysis, higher levels of walking at baseline were independently associated with response to fremanezumab (OR

conclusionPatients who spent more time walking before starting treatment, were more likely to have a response to fremanezumab. PA and TS levels changed since the first month and correlated with clinical variables.

Indexed as

Antibodies, MonoclonalExerciseMigraine DisordersAdultChronic DiseaseFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesTreatment OutcomeAntibodies, MonoclonalfremanezumabAntibodies, MonoclonalExerciseMigraine disordersSedentary behaviour

Identifiers

PMID39953381
PMCPMC11827165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.